Literature DB >> 29624883

Diagnosis and management of ADA2 deficient polyarteritis nodosa.

Andrea Human1, Christian Pagnoux2.   

Abstract

Deficiency of ADA2 (DADA2) is a recently described systemic inflammatory vasculopathy caused by mutations in the CERC1 gene that often, but not always, clinically resembles polyarteritis nodosa (PAN). The condition was originally characterized by livedoid rash, systemic inflammation, variable hypogammaglobulinemia, and early-onset stroke. The phenotypic spectrum has expanded to include patients with immunodeficiency syndromes and bone marrow dysfunction, which are not typical features of PAN. Exploration into the pathogenesis and treatment options of DADA2 has added to our understanding of this condition, but more studies are needed. The purpose of this article is to review the various clinical phenotypes of DADA2, and raise awareness among rheumatologists to consider DADA2 when evaluating patients presenting with PAN-like disease.
© 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  deficiency of ADA2; early-onset stroke; polyarteritis nodosa; vasculitis

Mesh:

Substances:

Year:  2018        PMID: 29624883     DOI: 10.1111/1756-185X.13283

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  3 in total

Review 1.  Clinical Approach to Diagnosis and Therapy of Polyarteritis Nodosa.

Authors:  Alojzija Hočevar; Matija Tomšič; Katja Perdan Pirkmajer
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

Review 2.  Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment.

Authors:  Benzeeta Pinto; Prateek Deo; Susmita Sharma; Arshi Syal; Aman Sharma
Journal:  Clin Rheumatol       Date:  2021-03-31       Impact factor: 2.980

Review 3.  Vasculitis, Autoimmunity, and Cytokines: How the Immune System Can Harm the Brain.

Authors:  Alessandra Tesser; Alessia Pin; Elisabetta Mencaroni; Virginia Gulino; Alberto Tommasini
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.